333732 RESULTS
COMMENT I am pleased to hear the positive news on donanemab and agree that it is likely to be approved soon. Donanemab has some potential advantages over lecanemab, but also may have some weaknesses, so it will be nice for clinicians to have both as options. Cert
COMMUNITY NEWS 2024-06-14 Community News After a favorable review from a Food and Drug Administration advisory committee, Eli Lilly’s donanemab appears poised for marketing approval in the U.S. (Jun 2024 news). Are clinics ready? While last year’s approval of lecanemab is helping
COMMENT The FDA Advisory Committee’s unanimous recommendation that donanemab receive full approval represents an important step forward in the treatment of Alzheimer’s disease. ARIA, the principal adverse event, is usually transient, asymptomatic, and manageable
COMMENT I commend the FDA PCNS Advisory Committee on a very thoughtful discussion today. I completely agree with the committee’s favorable conclusions regarding donanemab’s efficacy and risk/benefit profile. I also agree that the innovative and forward-thinking t
COMMENT The FDA advisory committee meeting held on June 10 for donanemab was another important advance for patients, families, and the field. Using the iADRS as the primary outcome variable, and the CDR-SB as a key secondary, the committee unanimously voted 11- 0
COMMENT The Perfect Meeting Three years ago, an FDA adviser called the agency’s approval of Aduhelm “probably the worst drug approval decision in recent U.S. history.” By contrast, a current adviser called today’s donanemab session “a perfect meeting.” FDA got th
COMMENT The in vivo detection of α-synucleinopathies represents a significant unmet need, and it is a highly challenging area of research. Several groups have been developing small molecules that could be utilized as positron emission tomography (PET) tracers for
COMMENT I applaud researchers who are developing new potential PET tracers for α-synuclein diseases, because the need is imperative, especially for use in studies determining target engagement of new drugs targeting misfolded α-synuclein. However, it is a challen
GRANT Friday, June 14, 2024- 3:15pm National Institutes of Health Application budgets are limited to $1,000,000 in direct costs per year. The maximum project period is 5 years. Letter of Intent due September 17, 2024. Application due October 17, 2024. https://g
GRANT Friday, June 14, 2024- 3:15pm National Institutes of Health A project period of up to five years may be requested. Funds may be requested for a minimum of 8 weeks and a maximum of 15 weeks of research education experience each year. Proposed, budgets cann
GRANT Friday, June 14, 2024- 3:15pm National Institute of Neurological Disorders and Stroke, National Institute on Aging Application budgets are limited to $500,000 in direct costs per year. The maximum project period is 4 years. October 04, 2024. https://grant
RESEARCH NEWS 2024-06-14 Research News In the decades after the World Trade Center collapse, people who cleaned up the rubble have developed post-traumatic stress disorder, lung problems, cancer, and cognitive impairment. They also seem to be at high risk for early onset dementia
RESEARCH MODELS Summary This knock-in (KI) mouse model was generated by introducing a D427V point mutation into exon 10 of the mouse Gba1 (glucosidase, beta, acid 1) gene, which corresponds to the human D409V mutation (The Jackson Laboratory; Polinski et al., 2021). The
PAPER Killinger B, Kordower JH, Walton S, Fenyi A, Tittle T, Choi S, Sidransky E, Paul G, Melki R
PAPER Zhang NR, Hatcher NG, Ekroos K, Kedia K, Kandebo M, Marcus JN, Smith SM, Bateman KP, Spellman DS
No filters selected
